AAV-Mediated Cone Rescue in a Naturally Occurring Mouse Model of CNGA3-Achromatopsia by Pang, Ji-jing et al.
AAV-Mediated Cone Rescue in a Naturally Occurring
Mouse Model of CNGA3-Achromatopsia
Ji-jing Pang
1,2*
., Wen-Tao Deng
1., Xufeng Dai
1,2,B oL e i
3, Drew Everhart
4, Yumiko Umino
4, Jie Li
1,
Keqing Zhang
3, Song Mao
1, Sanford L. Boye
1, Li Liu
1, Vince A. Chiodo
1, Xuan Liu
1, Wei Shi
1, Ye Tao
1,
Bo Chang
5, William W. Hauswirth
1
1Department of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, United States of America, 2Eye Hospital, School of Optometry and
Ophthalmology, Wenzhou Medical College, Wenzhou, China, 3Chongqing Key Laboratory of Ophthalmology, Ophthalmology, The First Affiliated Hospital of Chongqing
Medical University, Chongqing, China, 4Ophthalmology, SUNY Upstate Medical University, Syracuse, New York, United States of America, 5The Jackson Laboratory, Bar
Harbor, Maine, United States of America
Abstract
Achromatopsia is a rare autosomal recessive disorder which shows color blindness, severely impaired visual acuity, and
extreme sensitivity to bright light. Mutations in the alpha subunits of the cone cyclic nucleotide-gated channels (CNGA3) are
responsible for about 1/4 of achromatopsia in the U.S. and Europe. Here, we test whether gene replacement therapy using
an AAV5 vector could restore cone-mediated function and arrest cone degeneration in the cpfl5 mouse, a naturally
occurring mouse model of achromatopsia with a CNGA3 mutation. We show that gene therapy leads to significant rescue of
cone-mediated ERGs, normal visual acuities and contrast sensitivities. Normal expression and outer segment localization of
both M- and S-opsins were maintained in treated retinas. The therapeutic effect of treatment lasted for at least 5 months
post-injection. This study is the first demonstration of substantial, relatively long-term restoration of cone-mediated light
responsiveness and visual behavior in a naturally occurring mouse model of CNGA3 achromatopsia. The results provide the
foundation for development of an AAV5-based gene therapy trial for human CNGA3 achromatopsia.
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Introduction
The human retina contains about 6 million cone photorecep-
tors, which are responsible for fine resolution, central and color
vision. The distribution of cones increases from peripheral retina
to central macula or fovea that is comprised nearly 100% of the
cones. Achromatopsia is a relatively rare, autosomal recessive
congenital retinal disorder that is characterized by cone dysfunc-
tion. There are two clinical forms of achromatopsia: incomplete
and complete. Patients with incomplete achromatopsia display a
milder phenotype and retain residual cone function. Individuals
with complete achromatopsia suffer from severely reduced visual
acuity, pendular nystagmus, photophobia and color blindness.
Since the only functional photoreceptors in complete achroma-
topsia are rods, which are more sensitive to light, or become
saturate at higher levels of illumination, these individuals
experience extreme light sensitivity and daylight blindness [1–3].
Inhumans,fourgenesthatallencodeessentialcomponentsinthe
cone phototransduction cascade have been identified to cause
achromatopsia. Mutations in the two subunits (CNGA3, CNGB3)
of cone photoreceptor cyclic nucleotide-gated (CNG) channels
account for approximately 75% of all cases of complete achroma-
topsia[1,4–9].Someoftheremainingcasesarecausedbymutations
in alpha subunit of cone transducin (GNAT2) [10,11] and the
catalyticalphasubunitofconephosphodiesterase (PDE6C)[12,13].
In cone photoreceptors, CNG ion channels are integral tetrameric
plasmamembraneproteinscomposedoftwoA3andtwoB3subunits.
Photoreceptors respond to light by closure of the CNG channels
inducedbyhydrolysisofcGMP,resultinginmembranehyperpolar-
ization and decreased synaptic glutamate release [1,14]. A3 and B3
arerelatedproteinscomposedofsixtransmembranehelices(S1–S6),
apore-formingregionbetweenS5andS6,acyclicnucleotide-binding
domain (CNBD), and a C-linker region between S6 and CNBD,
which mediates channelgating [15,16].
The majority of mutations in the CNGA3 gene in human patients
identifiedsofararemissensemutations,suggestingthatCNGchannel
function has little tolerance for amino acid substitutions [6,9,17].
Missense mutations that ablate CNG channel function typically
occur at amino acid residues conserved among the members of the
CNG channel family. The majority of these changes are located
withinstructurallyandfunctionallyimportantregionsoftheCNGA3
polypeptide, i.e., the transmembrane helices, the pore, and the
cGMP-binding domain [9].
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recently discovered at The Jackson Laboratory exhibits an ocular
phenotype similar to complete human achromatopsia. The cpfl5
mouse carries a missense mutation in exon 5 of the Cnga3 gene [18].
AsinglenucleotideAtoGchangeatposition492inexon5resultsin
a substitution of alanine for threonine. The cpfl5 mouse exhibits
selectivelossofcone-mediatedlightresponsesaccompaniedbycone
cell loss, similar to the phenotype of complete achromatopsia
patientswithCnga3mutations.OurearlystudywithanAAV5vector
containing a human blue cone promoter (HB570) showed partial
restoration of cone function up to 2 months in cpfl5 mouse [18].
Others have shown partial restoration of cone function in a
CNGA3
-/- knock out mouse model using a capsid mutant AAV5
vectorcontainingamouseS-opsinpromoter[19].However,inboth
studies,conefunctionandcellsurvivalwereevaluatedinarelatively
short-term [18,19]. Moreover, in the later study, photopic b-wave
responses were restored only to an average of 1/3 of normal
amplitudes at 10 weeks post-injection. Here we report 5-month
preservation of cone structure and function in the cpfl5 mouse, a
natural missense Cnga3 mutant, when the therapeutic transgene is
driven by a CBA promoter in an AAV5 vector.
Results
AAV-mediated CNGA3 Expression in cpfl5 Mice
Gene therapy in the cpfl5 mouse was tested by subretinal
delivery of the mouse Cnga3 gene driven by the ubiquitous CBA
promoter packaged into an AAV5 vector. Subretinal injection was
performed at P14 before significant cone photoreceptor degener-
ation had initiated. As seen in normal mice (Fig. 1A, 1B),
immunostaining showed robust CNGA3 expression in the cone
outer segment (OS) layer of treated cpfl5 retina (Fig. 1D) 5 months
following treatment with AAV5-CBA-mCnga3 whereas the
contralateral uninjected eye lacked detectible CNGA3 labeling
(Fig. 1C). Colocalization of CNGA3 and cone-specific lectin
peanut agglutinin (PNA) staining suggests that CNGA3 expression
is targeted primarily to cone outer segments (Fig. 1E), and a small
amount was detected in cone cell bodies.
Cone Opsin Expression and Localization were Restored in
cpfl5 Mice
It has been shown previously that loss of CNGA3 resulted in
impaired expression and trafficking of cone opsins as well as cone
cell death in the Cnga3
-/- mouse [20]. Here we documented the
retinal morphology and expression patterns of M- and S-cone
opsins in cpfl5 mice (Fig. 2). 5-month-old cpfl5 mice (Fig. 2B)
exhibited photoreceptor outer & inner segment lengths and outer
nuclear layer thickness similar to normal C57 BL/6J mice
(Fig. 2A). However, retinal wholemounts stained with cone outer
segment sheath specific PNA (green) revealed that moderate cone
structure loss had occurred at this time point, primarily in the
inferior (ventral) and nasal regions of the retina (Fig. 2D). Cone
densities in these regions (Fig. 2D) have decreased compared to the
dorsal (superior) and temporal regions of the normal retina
(Fig. 2C). Expression and localization of cone opsins were then
analyzed at different ages in cpfl5 eyes by immunostaining retinal
sections with antibodies to M- or S-opsin. 3-week-old cpfl5 mice
(Fig. 3B) exhibited M-opsin staining intensity and localization to
OS consistent with that of wild type controls (Fig. 3A). However,
by 10 weeks of age, M-opsin was mislocalized to the inner
segment, cone nuclei, and cone pedicles (Fig. 3C). The loss of S-
opsin staining proceeded more rapidly than M-opsin. In 3-week-
old cpfl5 mice (Fig. 4B), the intensity of S-opsin immunostaining
started to decrease (Fig. 4A), but still localized in the OS.
However, by 10 weeks of age, no S-opsin staining was seen in cpfl5
mice indicating that profound S-cone OS loss had occurred
(Fig. 4C).
To evaluate whether AAV5-CBA-mCnga3 treatment could
arrest cone opsin loss and maintain its normal OS localization
following P14 treatment, we analyzed retinal sections from
untreated and contralateral treated cpfl5 eyes with M- and S-
opsin antibodies at 5 months after treatment. In untreated eyes,
M-opsin can be detected in the superior retinal hemisphere but
rarely in the inferior hemisphere (Fig. 3D). This is consistent
with PNA staining showing that cones are preserved in the
superior region at this age (Fig. 2B). As noted above however,
the remaining M-opsin was mislocalized to the inner segments,
cone nuclei, cone pedicles (Fig. 3E). In contrast, in vector-
treated contralateral eyes, more intense M-opsin staining was
detected throughout the retina (Fig. 3G), with an exclusive OS
localization pattern (Fig. 3F). In untreated eyes, virtually no S-
opsin staining can be detected in any part of the retina (Fig. 4D,
4E) whereas in treated eyes S-opsin was detected throughout the
retina and was localized primarily in the cone OS (Fig. 4G, 4F).
In summary, AAV5-CBA-Cnga3 P14 treatment prevented cone
degeneration and maintained normal M- and S-opsin expression
and localization in the cpfl5 mice for at least 5 months.
Cone Function is Restored in AAV-treated cpfl5 Mice
We find that cpfl5 mice treated with AAV5-CBA-mCnga3 vector
significantly restored cone photoreceptor function as measured by
Figure 1. AAV5-CBA-mCnga3 leads to CNGA3 expression specifically in cone photoreceptors. A. CNGA3 expression (red) in a normal
C57BL/6J mouse. B. Same field as (A) with PNA staining (green) to show CNGA3 expression in cones. C. No CNGA3 expression was found in an
untreated cpfl5 eye. D. AAV-mediated expression of CNGA3 (red) in cone photoreceptors of the partner treated cpfl5 eye. E. Same field as (D) with
PNA staining (green) to show CNGA3 expression in cones. OS, outer segments; IS, inner segments.
doi:10.1371/journal.pone.0035250.g001
Gene Therapy to cpfl5 Mice with Cnga3 Mutation
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35250Figure 2. Cone photoreceptors degenerate in cpfl5 mice. Representative light microscopic images of retinal paraffin sections from the superior
hemisphere of a normal 5 month old C57BL/6J (A) and an age matched cpfl5 mouse (B) showing similar appearing outer and inner nuclear layers.
Whole mount PNA staining (green dots) of a 5 month C57BL/6J retina (C, right eye): and a cpfl5 retina at 5 months (D, left eye) showing that cones
outside the superior hemisphere, primarily in the nasal inferior quadrant of the cpfl5 retina where most of the S-cones are located have degenerated.
Panels A and B and Panels C and D are at the same scale.
doi:10.1371/journal.pone.0035250.g002
Figure 3. AAV-mediated CNGA3 expression restores expression and localization of M-opsin in cpfl5 mice. By immunostaining, a 3-
week-old C57 BL/6J wild type control retinal section (A) and an age-matched cpfl5 retina (B) has identical expression and localization of M-opsin in the
outer segments. In contrast, a section of a 10-week-old cpfl5 mouse (C) shows that M-opsin has become mislocalized to cone inner segments, nuclei,
and synaptic termini. Upon CNGA3 vector treatment, M-opsin expression and localization is nearly normal (D-G). Retinal sections from untreated (D
and E, E is inset of D) and the contralateral treated (F, G, F is an insert of G) cpfl5 eyes at 5 months post-treatment show that M-opsin can be detected
only in the superior region (arrow) of the retina in an untreated 5-month-old cpfl5 mouse (D); in addition, the remaining M-opsin in superior (dorsal)
region is mislocalized (E). In contrast, intense M-opsin staining was detected throughout the entire retina in the contraleteral vector-treated eye (G)
and was exclusively localized to the cone outer segments (F). Scale bars are equal to 50 mm.
doi:10.1371/journal.pone.0035250.g003
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and light-adapted single-stimulus ERG analyses were initiated at 3
weeks post-treatment (Fig. 5A, 5B), and repeated regularly until 5
months post-treatment. At 3 weekspost-injection, the average light-
adapted b-wave amplitude (Fig. 5C, 5D) was 82 6 16 mV (n=3) in
treated eyes, about 80% of the wild-type controls (652 6 55 mV,
n=3, P=0.09) at a stimulus intensity of 1.08 log cd-s/m
2. No ERG
responses were detected in untreated eyes (2 6 2.6 mV, n=3).
Althoughtheuntreatedcpfl5(561631 mV)andnormalC57BL/67
eyes (652 6 55 mV) had statistically similar dark-adapted b-wave
amplitudes (n=3, P=0.19), there was a reduction in the average of
dark-adapted b-wave amplitude in treated eyes (427 6 23 mVa t
0.43 log cd-s/m
2) vs. in untreated eyes (561 6 31 mV, n=3, P,
0.05) (Fig. 5A, 5B. This decreased rod-mediated ERG amplitude
upon treatment is likely the consequence of injection-related
damage since this difference diminished (P.0.05) when the same
mice were similarly analyzed at 5 months post-injection (Fig. 5F,
5H). We have consistently observed that rod-mediated ERG
responses in 5.5 months old untreated cpfl5 eyes were lower than
the age-matched wild-type controls (P,0.05), and the reason is
under investigation.
At 5 months post-injection, the average light-adapted ERG
response in treated cpfl5 was 58.40 6 18.87 mV (n=3), about 70%
of the wild-type controls at a stimulus intensity of 0.65 log cd-s per
m
2 (Fig. 5E, 5F). 10 Hz flicker ERG (Fig. 5G, 5H) showed that
untreated and treated cpfl5 eyes at lower stimulus intensities (# -
1.85 log cd-s per m
2) which reflect pure rod-mediated responses
[21], were similar. At high stimulus intensities (. -1.85 log cd-s per
m
2), cone-driven responses in treated eyes showed much higher
amplitudes than partner untreated eyes. The average b-wave
amplitudes plotted against light intensities from untreated,
contralateral treated, and wild type control eyes (Fig. 5H) showed
a cone peak of 68.29 6 15.19 mV in the treated eyes at 0.65 log cd-
s/m
2 whereas a signal is undetectable in untreated eyes (n=3, P ,
0.01). These cone ERG responses in the treated eyes were about
60% of that recorded in the same session from uninjected wild type
controls (113.68 6 26.61 mV, n=5). In summary, cone-mediated
ERG responses were restored and maintained for at least 5 months
in AAV5-CBA-mCnga3 treated eyes.
Restoration of Cone-mediated Acuity and Contrast
Sensitivity in cpfl5 mice
We also tested whether maintenance of cone structure, normal
cone opsin localization and restoration of cone ERG function
translated into improvement in cone-mediated visual behavior by
measuring optomotor responses to rotating sine-wave gratings
[22,23]. Optomotor behavioral analysis revealed significant im-
provementincone-mediatedacuityandcontrastsensitivityofAAV-
treated cpfl5 eyes. Untreated eyes displayed poor visual acuities of
0.273 6 0.111 cycles per degree whereas in treated eyes, acuities
were 0.457 6 0.059 cycles per degree (Fig. 6A), a level essentially
identical to that in wild type controls (0.477 6 0.026) and
significantly better than untreated cpfl5 eyes (n=4, P,0.05). In
parallel, contrast sensitivities tested at a spatial frequency of 0.256
cycles/degree in treated eyes (9.20 6 2.30, n=4) showed similar
contrast thresholds as wild type controls (8.49 6 2.78, n=4), and
were significantly better than untreated eyes (2.34 6 0.74, P,0.01,
n=4; Fig. 6B). Thus, cone-mediated visual acuity and contrast
sensitivitywererestoredtowildtypelevels,demonstratingapositive
therapeutic effect on visual behavior in treated cpfl5 mice.
Discussion
We demonstrate here that AAV5-CBA-mCnga3-mediated gene
replacement therapy restored cone-specific ERG, cone-mediated
visual acuity and visual contrast in the cpfl5 mouse, a naturally
Figure 4. AAV-mediated CNGA3 expression maintains expression and localization of S-opsin in cpfl5 mice. Retinal sections
immunostained with S-opsin antibody from 3-week-old C57 BL/6J wild type control mouse (A) and an age-matched cpfl5 retina (B) showing robust S-
opsin expression in cone outer segments. Section from a 10-week-old cpfl5 retina (C) showed no S-opsin staining indicating that profound S-cone
degeneration had occurred. Five months after vectored CNGA3 expression, a treated cpfl5 retina maintained normal expression and localization of S-
opsin immunostaining (G and inset F) for at least 5 months in contrast to the contralateral untreated retina (D and E). Scale bars equal 50 mm.
doi:10.1371/journal.pone.0035250.g004
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35250Figure 5. AAV5-CBA-mCnga3 treatment restores cone-mediated ERG. A-D. Single-stimulus ERG recordings from cpfl5 mice 3 weeks post-
treatment compared with normal C57BL/6J controls. Representative rod-mediated (A) ERG responses and statistical analysis (B) of b-wave amplitudes
at 0.43 log cd-s per m
2. Representative cone-mediated ERG (C) responses and statistical analysis (D) of b-wave amplitudes at 1.08 log cd-s per m
2.
n=3 for each group. G-H. 10 Hz flicker ERG recordings from cpfl5 mice 5 months post-treatment compared with normal C57BL/6J controls.
Representative dark-adapted 10Hz flicker ERG (G) from normal C57 BL/6J, untreated and the contralateral treated cpfl5 eyes. Statistical analysis (H)
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deficiency. We also showed that gene therapy restored normal
levels and localization of cone opsins. These therapeutic effects
were maintained for at least 5 months after treatment.
We previously reported that AAV5-mediated gene therapy
using the HB570 human blue cone opsin promoter (HB570)
[18,24] or human red/green opsin promoter (PR2.1) (our
unpublished work) leads to partial restoration of both S- and M-
cone visual function in cpfl5 mice. A recent study using an AAV5
vector with a surface exposed tyrosine to phenylalanine mutation
on the capsid (Y719F) containing a mouse S-opsin promoter also
demonstrated partial cone functional restoration in a CNGA3
-/-
mouse model 11 weeks after injection [19]. In that study photopic
b wave responses were on average 1/3 the amplitude of matched
wild type controls. Compared to both previous studies, our current
results using the strong, fast acting CBA promoter showed more
robust and longer term restoration of ERG amplitudes, and vision
elicited behavior.
Based on immunostaing using a CNGA3-specific antibody,
CNGA3 expression driven by CBA promoter was primarily
restricted to cone photoreceptors of cpfl5 retina with majority of
CNGA3 found in the cone OS where it is normally localized,
suggesting that off-target expression is inefficient, likely due to a
posttranscriptional process mediating the instability of CNGA3
protein in non-cone cells. This phenomenon is not unexpected,
particularly when the treatment is longer than 2–3 months.
Similar observations of cell specific expression have also been
found when using CBA or a truncated version of CBA (smCBA) to
express RPE65 in the RPE cells [25],GC1 [26] and PDEb proteins
[27,28] in photoreceptors. In addition, the RPE65-LCA clinical
trials have demonstrated the ability of the CBA promoter to
support therapeutic transgene expression in the retina and
restoration of visual function [29–33]. Although a cone-specific
promoter might be preferred if off-target expression from a CBA
promoter is a concern, it remains unclear which promoter would
be best for transducing all cone subtypes. The human blue cone
promoter (HB570) [18] or 2.1 kb human red/green opsin
promoter (PR2.1. unpublished work) used in our previous cpfl5
mice studies, or the mouse S-opsin promoter used in the CNGA3
knockout mice study [19] have not been investigated in non-
human primates. In fact, when evaluated in dog, the HB570
promoter did not drive expression in S-cones, only in M/L cones.
Therefore, the current study using the CBA promoter combined
with AAV5 serotype might remain the preferred combination of
promoter and AAV serotype.
GFP expression in photoreceptor cells from AAV5-CBA-GFP
vector can be detected as early as 7 days after subretinal injection
[34]. Early onset AAV5 expression is also supported by the fact
that almost half the magnitude of the final cone ERG restoration is
obtained one week after P14 injection with AAV5-CBA-Cnga3
vector (data not shown). It takes about 3 weeks for the AAV5-
CBA- Cnga3 vector to express sufficient CNGA3 protein to restore
a stable cone ERG function (Figure 1A &1B). Cone opsins are
almost normal in untreated 3-week-old cpfl5 mice (Figure 3 & 4)
and cone structure is intact by whole mount PNA staining at P35
(data not shown). That explains why we can maintain most of the
cone opsins 5-month after P14 treatment.
The rapid loss of S-opsin labeling in cpfl5 mouse suggests
treatment earlier than P14 might lead to even more recovery of
cone function, however, it is difficult to detach a significant
fraction of the mouse retina prior to eye opening at P14 via
trans-cornea subretinal injection without substantial injection-
related damage [27,34]. We have noted a close correlation
between maximal stable rescue and the extent of retinal
coverage by the vector. For example, P14 treatment [27] was
more therapeutically robust than P2 treatment in the rapid
degenerating rd10 mouse that carries a PDEb mutation [35].
Unlike the human retina, in which of the density of cones is
very high in the central macula (fovea), M- and S-cones in the
mouse retina are relatively evenly distributed in fixed topo-
graphic patterns across the entire retina. Currently, the most
reliable way to evaluate successful cone therapy in mouse would
be to limit analysis to eyes where the majority of cone
photoreceptors were transduced, i.e. in retinas in which
subretinal vector had detached all or nearly all of the retina.
We found one microliter of vector sufficient to detach nearly
the entire mouse retina, resulting in a homogenous ‘‘shallow
bleb’’, which appears to minimize subsequent retinal detach-
ment-related photoreceptor loss. From our previous work on
cone therapy in the rd12 (mutant RPE65) mouse, we found that
a single subretinal injection of AAV-RPE65 can restore cone
ERG amplitudes to about 2/3 of wild type levels [25], similar
to that reported here. This approach may therefore, in part,
explain the better cone ERG rescue reported here than
previously [19], in which subretinal vector detached only 30%
of the retina.
It has been shown that AAV vectors with capsid surface exposed
tyrosine residues mutated to phenylalanine (Y-F) have increased
transgene expression levels and transduction kinetics relative to the
corresponding standard wild-type AAV vectors [36]. An AAV8 Y-
F capsid mutant vector demonstrated more effective and longer
therapeutic effect compared to standard AAV8 and AAV5 in the
rd10 mouse model of retinal degeneration [28]. A side by side
comparison of AAV5 and the AAV5 (Y719F) utilized in the
Michalakis et al. study [19] was not presented, therefore, it is
uncertain whether there is any advantage of AAV5 (Y719F) over
unmutated AAV5 for achieving cone rescue. In our case, perhaps
the robust nature of CBA expression precluded the need for an
AAV5 capsid variant. It may also be that the differences in level of
rescue are related to the fact that the two studies were performed
in different mouse models of CNGA3 deficiency.
Both cpfl5 and CNGA3
-/- mice display the essential hallmarks
of achromatopsia observed in human patients, in which cone
responses are absent whereas rod function is retained [18,20,37].
In both mouse strains, cones gradually degenerated, possibly as a
result of the impaired phototranduction cascade or the structural
instability of cone outer segments [20]. Both models displayed
defective cone opsin transport and failure to target cone opsin to
the outer segments. Cones in the dorsal (superior) hemisphere
containing mainly M-opsin survived significantly longer than
ventral (inferior) cones with primarily S-opsin. Interestingly, the
same pattern of S-cone loss preceding M-cone loss has been
observed in other mouse models of retinal degeneration [38,39].
In 5-month-old cpfl5 eyes, M-opsin can be only detected in
superior region of the retina, and is mislocalized to inner segments
and cone cell bodies (Fig. 3D). However, M-cone structure in
superior retina is still relatively intact as shown by cone outer
segment sheath specific PNA staining (Fig. 2D).It would be
interesting to test whether delayed treatment in older cpfl5 mice
would still lead to rescue of the remaining M-cones as has been
showed that the cone-mediated ERG amplitudes were restored up to 60% of wild type levels for at least 5 months post-treatment; short arrow: pure
rod-mediated responses; long arrow: pure cone-mediated responses. NS: No statistical difference; *: P,0.05.
doi:10.1371/journal.pone.0035250.g005
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intracellular M-opsin distribution should also be restored since
cone cell bodies are still be present although cone functional
degeneration has occurred early. This would have important
implications for human Cnga3 achromatopsia which is character-
ized by a gradual and variable degree of cone loss [9,40].
In summary, we demonstrate restoration of cone function for at
least 5 months in a naturally occurring mouse model of Cnga3
achromatopsia using an AAV5 vector. Both M-cone and S-cone
degeneration was prevented and correct trafficking of cones opsins
restored. As mutations in CNG channels are the most common
cause of human achromatopsia (CNGB3 $ 50%, CNGA3 $
25%), the demonstration of successful gene therapies by AAV
vectors to rescue cone function in this model [18,41], in CNGB3-
mutant dogs [42] and in Cnga3
-/- mice [19] provides key proof-of-
principle for future achromatopsia clinical trials in humans.
Materials and Methods
Animals
Cpfl5 mice and the isogenic wild type strain C57BL/6J mice
were obtained from The Jackson Laboratory (Bar Harbor, ME).
All mice were bred and maintained in the University of Florida
Health Science Center Animal Care Services Facilities under a
12hr/12hr light/dark cycle. All experiment protocols were
approved by the University of Florida Institutional Animal Care
and Use Committee and conducted in accordance with the
Association for Research in Vision and Ophthalmology (ARVO)
Statement for the Use of Animals in Ophthalmic and Vision
Research and National Institute of Health (NIH) regulations.
Construction of the AAV5-CBA-mCnga3 Vector
Serotype 5AAVvectorswereusedinthisstudyastheyhavebeen
demonstrated previously to mediate robust transduction efficiency
and relatively rapid expression onset in photoreceptors [43]. A
Mammalian Gene Collection (MGC) clone that contains full length
mouseCnga3cDNAwaspurchasedfromInvitrogen(Carlsbad,CA).
NotIrestrictionenzymesiteswereaddedtobothendsofthecDNAby
PCR utilizing forward 59 –TTAGCGGCCGCGCAGAGATGG-
CAAAGGTGA- 39 and reverse 59 –TTAGCGGCCGCTG-
CATTTTCAGTCAGTCTTTGAA-39 primers. The PCR frag-
ment was then cloned into pCRblunt plasmid (Invitrogen) and
sequenceverified.UsingtheAAVvectorplasmidpTR-CBA-hGFP,
containing the CBA promoter driving expression of GFP, the hGFP
cDNA was replaced with mCnga3 via NotI digestion. AAV vectors
were packaged and tittered according to previously published
methods [44,45].
Subretinal Vector Injection
One microliter of AAV5-CBA-mCnga3 vector containing 10
10
total DNAse resistant vector genomes was injected subretinally
into the left eye of each P14 cpfl5 mouse (n=30) and the right eyes
remained uninjected as controls. Subretinal injections were
performed as described previously [27,28,38,39]. Only those mice
that had more than 95% retinal detachment and minimal
complications following subretinal injections were kept for further
evaluation [25]. Eighteen cpfl5 mice (60% of total) met this
criterion, which resulted in at least three animals for each
experiment.
Electroretinographic Analysis
InitialERGresponsesofcpfl5miceandisogenicwildtypecontrols
wererecordedat3weeksfollowinginjection,andrepeatedatthe3
rd
and 5
th month post-treatment using a Toennies Multiliner Vision
instrument (Ho ¨chberg, Germany) according to protocols described
previously [26,39,46]. Briefly, mice were dark adapted overnight
andanesthetizedwithamixtureof100 mg/kgketamine,20 mg/kg
xylazineandsalineataratioof1:1:5.FullfieldERGswererecorded
using gold wire loop electrodes placed on each cornea and a
reference electrode placed subcutaneously between the eyes.
Scotopic rod recordings were performed with seven increasing light
intensities of white light between 0.01 mcds/m
2 and 5 cds/m
2. Ten
responses were recorded and averaged at each light intensity.
Photopicconerecordingsweredoneaftermicewerelightadaptedto
awhitebackgroundlightof100 cds/m
2for5 min.Recordingswere
performed with five increasing flash intensities between 100 mcds/
m
2 and 12 cds/m
2 in the presence of a constant 100 mcds/m
2 rod
suppressing background light. Fifty responses were recorded and
averaged at each intensity. Photopic b-wave amplitudes from
untreated, treated cpfl5 and wild type eyes at each intensity were
averaged and compared by repeated-measures ANOVA with the
BonferroniposthoctestforANOVA(P,0.05)tocomparemeansat
individual flash intensities.
Figure 6. Rescue of visual acuity and contrast sensitivity in cpfl5 mice. Comparison of average values for photopic acuities (A) and contrast
sensitivities (B) from untreated, treated, and wild type mice (n=4 for each group) 5 months post injection. Values are expressed as the mean 6 SD for
each group (* P , 0.05 for acuity and P,0.01 for contrast sensitivity).
doi:10.1371/journal.pone.0035250.g006
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untreated, treated cpfl5 and wild type control eyes were analyzed
with a custom-designed ERG system with a Ganzfeld illumination
using Grass PS22 Xenon visual stimulator (Grass Instrument Inc.
West Warwick, RI). Procedures were performed as described
previously [39]. ERG data are presented as mean 6 standard
deviation (mean 6 SD). Statistical significance was examined with
ANOVA as above. Pairwise comparisons between groups for the
ERG were performed by the Bonferroni post hoc test (P , 0.05).
Optomotor Testing
Photopic and scotopic visual acuities and contrast sensitivities of
treated and untreated mouse eyes were measured using a two-
alternative forced choice paradigm as described previously
[22,23,26,39] with minor modifications. Acuity was defined as
the highest spatial frequency (100% contrast) yielding a threshold
response, and contrast sensitivity was defined as 100 divided by the
lowest percent contrast yielding a threshold response (sinusoidal
pattern at 0.256 cycles/degree). For both photopic and scotopic
acuity, the initial stimulus was a 0.200 cycles/degree sinusoidal
pattern with a fixed 100% contrast. For photopic contrast
sensitivity measurements, the initial pattern was presented at
100% contrast, with a fixed spatial frequency of 0.256 cycles/
degree. For scotopic contrast sensitivity measurements, the spatial
frequency was fixed at 0.031 cycles/degree, a spatial frequency
tuned for rod vision [22]. All patterns were presented at a speed of
12 degrees per second. Photopic vision was measured at a mean
luminance of 70 cd/m
2. For scotopic measurements, mice were
dark-adapted overnight and light levels were attenuated to 3.5 6
10–
5 cd/m
2 through the use of neutral density filters. Visual
acuities and contrast sensitivities were measured for both eyes of
each mouse four to six times over a period of 1–2 weeks. Wild type
control animals were 6 months old at testing time (n=5), and P14
treated animals were at least 5.5 months old (n=5). Unpaired t-
tests were carried out on acuity and percent contrast values to
determine significance of results.
Tissue Preparation and Immunohistochemistry
Eyes were enucleated at 5 months after P14 treatment. Retinal
sections were prepared according to previously described methods
[34,39]. Briefly, immediately following sacrifice, the limbus of
injected and uninjected eyes was marked at ‘‘12 o’clock’’ with a
hot needle which facilitated orientation. The eyes were then
enucleated and fixed in 4% paraformaldehyde overnight. The
cornea and lens were then removed from each eye without
disturbing the retina. The remaining eyecup was rinsed with PBS
and then cryoprotected by placing it in 30% sucrose in PBS for 4
hours at 4u. Eyecups were then embedded in cryostat compound
(Tissue TEK OCT, Sakura Finetek USA, Inc., Torrance, CA) and
frozen at - 80uC.
Retinal cryosections were cut at 12mM thickness, then rinsed in
PBS and blocked in 2% normal goat serum, 0.3% Triton X-100 in
1% BSA in PBS for 1 hour at room temperature. Lectin PNA
conjugated to a Alexa Fluor 488 (1: 200, L21409, Invitrogen), S-
cone opsin, M-cone opsin primary antibodies (1:200, Santa Cruz
Biotechnology, Santa Cruz, CA), or rabbit polyclonal CNGA3
(generously provided by Dr. Martin Biel (Ludwig-Maximilians-
Universita ¨t,Mu ¨nchen) was diluted to 1:400 in 0.1% Triton X-100
and 1% BSA in PBS, and incubated overnight at 4uC. The
sections were then washed 3 times with PBS, then incubated with
IgG secondary antibody tagged with Alexa-594 (molecular Probes,
Eugene OR) diluted 1:500 in PBS at room temperature for 1 hour
and washed with PBS. Sections were mounted with Vectashiled
Mounting Medium for Fluorescence (H-1000, Vector lab, In.
Burlingame, CA) and coverslipped. Sections were analyzed with a
Zeiss CD25 microscope fitted with Axiovision Rel. 4.6 software.
All fluorescent images were acquired using identical exposure
settings.
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